Edgar Filing: MITCHELL DEAN J - Form 4

MITCHELL	DEAN J												
Form 4													
May 02, 2019	9												
FORM 4 LINITED STATES SECURITIES AND EXCHANCE COMMISSION											OMB APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION									-	3235-0287			
Check thi	s box		Was	hington	ı, I	D.C. 205	549			Number:			
if no longer whiat to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI							Expires:	January 31, 2005					
subject to		EMENT O	F CHAN				CIA	LOW	NERSHIP OF	Estimated a	Estimated average		
Section 1									burden hou	burden hours per			
Form 4 or Form 5			~			a				response	response 0.5		
obligation	• • • • • • • •								ge Act of 1934,				
may conti				•		•	- ·		of 1935 or Sectio	on			
See Instru	iction	30(h)	of the Inv	vestmen	it C	Company	y Aci	of 19	40				
1(b).													
(Print or Type R	Responses)												
1. Name and Address of Reporting Person * 2. Issuer MITCHELL DEAN J Symbol Therava				r Name and Ticker or Trading					5. Relationship of Reporting Person(s) to				
									Issuer				
				nce Bio	ph	arma, Ir	nc. [T	BPH]	(Check all applicable)				
(Last)	(First)	(Middle)	3. Date of	Earliest 7	Гra	nsaction			(Chev	ex un applicable			
			(Month/D	/Day/Year)					_X_ Director10% Owner				
C/O THERAVANCE BIOPHARMA 04/30/20				-					Officer (give title Other (specify				
US, INC., 90	01 GATEWA	Y BLVD							below)	below)			
				nendment, Date Original onth/Day/Year)					6. Individual or Joint/Group Filing(Check				
									Applicable Line)				
X Form file							y One Reporting Person						
SOUTH SA	N								Person	More than One R	eporting		
FRANCISC	O, CA 94080								1 013011				
(City)	(State)	(Zip)	Table	e I - Non-	De	erivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficia	lly Owned		
1.Title of	2. Transaction I	Date 2A. Dee	amed 3. 4. Securities						5. Amount of	6. Ownership	7. Nature of		
Security	(Month/Day/Ye	on Date, if TransactionAcquired (A) or						Securities	Form: Direct	Indirect			
(Instr. 3)		any	Code Disposed of (D)						•	· /	Beneficial		
	(Month/	Day/Year)	(Instr. 8) (Instr. 3, 4 and 5)			5)		· · ·	Ownership (Instr. 4)				
									Reported	(111501. 4)	(Instr. 4)		
							(A)		Transaction(s)				
				Code	v	Amount	or (D)	Price	(Instr. 3 and 4)				
Ordinary	04/00/0010				•				04.571	D			
Shares	04/30/2019			А		8,385	А	\$0	34,571	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: MITCHELL DEAN J - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration D	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Share Option (Right to Buy)	\$ 23.85	04/30/2019		А	6,000)	<u>(1)</u>	04/29/2029	Ordinary Shares	6,000	

Reporting Owners

		Relationships						
Reporting Owner Name / Address	Ι	Director	10% Owner	Officer	Other			
MITCHELL DEAN J C/O THERAVANCE BIOPHARMA US 901 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080	S, INC.	Х						
Signatures								
Brett A. Grimaud, Attorney-in-Fact	05/02/2019)						
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each

(1) continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.